Clinical Trial

Carotenoid Supplementation During Pregnancy

Study Description

Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects

This study is designed to test the hypotheses that (1) the third trimester of pregnancy is a period of maternal systemic and ocular carotenoid depletion; (2) prenatal supplementation with 6.0 milligrams of lutein and 0.5 milligrams of zeaxanthin will have significant effects on ocular and systemic biomarkers of maternal and infant carotenoid status relative to a matched, standard-of-care prenatal supplement without added lutein and zeaxanthin; and (3) newborn infants with the highest systemic and ocular carotenoid status will have more mature foveal structure. Mothers will be enrolled in the study during their first trimester, and will take the study carotenoid or control supplements for 6 to 8 months. The final study outcome measurements of mothers and infants will be completed within two weeks of the baby's birth.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Carotenoid Group

DHA Softgel active ingredients: DHA 200 mg, d-Alpha Tocopherol 30 IU, Lutein 6mg

Dietary Supplement - Control Group

DHA Softgel active ingredients: DHA 200 mg, d-Alpha Tocopherol 30 IU

Additional Information

Official Study Title

Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects

Clinical Trial ID

NCT03750968

ParticipAid ID

av2mra